<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084461</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01449</org_study_id>
    <secondary_id>0425</secondary_id>
    <secondary_id>NCI-6325</secondary_id>
    <secondary_id>OSU-2003C0085</secondary_id>
    <secondary_id>CDR0000365313</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00084461</nct_id>
  </id_info>
  <brief_title>Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of romidepsin in treating patients who have locally&#xD;
      advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin,&#xD;
      work in different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine objective response rate in patients with locally advanced or metastatic&#xD;
      neuroendocrine tumors treated with FR901288 (romidepsin).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity of this drug in these patients. II. To measure serum tumor markers&#xD;
      (pancreastatin, gastrin, pancreatic polypeptide, glucagon, substance-P, neurotensin,&#xD;
      calcitonin, somatostatin, vasoactive intestinal peptide, gastrin releasing polypeptide, ACTH)&#xD;
      depending on the tumor type pre-, during-, and post-treatment.&#xD;
&#xD;
      III. To perform a nuclear medicine functional imaging scan (octreoscan) to evaluate the&#xD;
      disease status pre-, during-, and post-treatment.&#xD;
&#xD;
      IV. To perform histone acetylation assay in cytospins from peripheral blood mononuclear cells&#xD;
      (PBMCs) to correlate with disease response and with immunologic parameters.&#xD;
&#xD;
      V. To quantify gene expression by Real Time PCR of type 1 and type 2 cytokines,&#xD;
      co-stimulatory molecules, and adhesion molecules in PBMCs obtained from the pre-, during-,&#xD;
      and post-treatment blood samples.&#xD;
&#xD;
      VI. To perform a multicolor flow cytometric analysis on fresh blood to assess activation of&#xD;
      lymphocyte subsets and presence of co-stimulatory and adhesion molecules.&#xD;
&#xD;
      VII. To perform in vitro functional assays for innate as well as antigen-specific T cell&#xD;
      immune responses in PBMCs obtained from the pre-, during-, and post-treatment blood samples.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28&#xD;
      days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving complete remission (CR) receive 2 additional courses beyond CR.&#xD;
&#xD;
      Patients are followed at 2-4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Frequency of response will be estimated with a 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Gastrinoma</condition>
  <condition>Glucagonoma</condition>
  <condition>Insulinoma</condition>
  <condition>Metastatic Gastrointestinal Carcinoid Tumor</condition>
  <condition>Pancreatic Polypeptide Tumor</condition>
  <condition>Pulmonary Carcinoid Tumor</condition>
  <condition>Recurrent Gastrointestinal Carcinoid Tumor</condition>
  <condition>Recurrent Islet Cell Carcinoma</condition>
  <condition>Regional Gastrointestinal Carcinoid Tumor</condition>
  <condition>Somatostatinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed carcinoid tumor or islet cell neuroendocrine tumor&#xD;
&#xD;
               -  Well- or moderately-differentiated tumor&#xD;
&#xD;
          -  Metastatic and/or locally advanced disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Unidimensionally measurable lesion at least 20 mm by conventional techniques OR&#xD;
                  at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Lesions in a previously irradiated area are not considered measurable&#xD;
&#xD;
               -  No truly non-measurable lesions, including the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  Ineligible for standard treatment&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
          -  WBC &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled dysrhythmias&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No serious ventricular arrhythmia, defined as ventricular tachycardia or ventricular&#xD;
             fibrillation &gt;= 3 beats in a row&#xD;
&#xD;
          -  No left ventricular hypertrophy by EKG&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  LVEF &gt; 40% by resting MUGA&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to study drug&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy (e.g., interferon alfa)&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  More than 12 weeks since prior hepatic artery chemoembolization unless liver lesions&#xD;
             are not the only indicator lesions&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy regimen for carcinoid or islet cell tumor&#xD;
             (other than hepatic artery chemoembolization)&#xD;
&#xD;
          -  More than 4 weeks since prior oral or IV steroids (first 16 patients only)&#xD;
&#xD;
          -  Concurrent long-acting octreotide allowed at standard doses if dose has been stable&#xD;
             for the past 12 weeks&#xD;
&#xD;
               -  Concurrent subcutaneous octreotide for breakthrough use for symptomatic relief&#xD;
                  allowed&#xD;
&#xD;
          -  No concurrent systemic steroids (first 16 patients only)&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior investigational tumor-specific therapy&#xD;
&#xD;
          -  No other prior histone deacetylase inhibitors (e.g., valproic acid)&#xD;
&#xD;
          -  No concurrent hydrochlorothiazide&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha Shah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Insulinoma</mesh_term>
    <mesh_term>Carcinoma, Islet Cell</mesh_term>
    <mesh_term>Gastrinoma</mesh_term>
    <mesh_term>Glucagonoma</mesh_term>
    <mesh_term>Somatostatinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

